NCT06815536

Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,291 (estimated)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer: Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result? Specimens that are collected for routine clinical care and harbor Neisseria gonorrhoeae will be evaluated in this study.

Detailed description

This is a prospective, multi-center, cross-sectional study using consecutive clinical specimens that are collected for routine clinical care and test positive for N. gonorrhoeae using an FDA-cleared molecular assay. The study evaluates the diagnostic accuracy of multiple investigational reflex tests to detect the mutant allele gyrA 91F that predicts ciprofloxacin resistance in N. gonorrhoeae, as compared to a reference standard of Sanger sequencing of the gyrA codon 91. Specimens will be tested via a reference standard of Sanger sequencing and one investigational reflex test. The target sample size is 311 urine specimens, 496 vaginal swab specimens, and 469 pharyngeal specimens, for each investigational reflex test.

Conditions

• Neisseria Gonorrheae Infection

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Investigational Reflex Test 1	Investigational Reflex Test 1
DIAGNOSTIC_TEST	Investigational Reflex Test 2	Investigational Reflex Test 2
DIAGNOSTIC_TEST	Investigational Reflex Test 3	Investigational Reflex Test 3

Timeline

• Start date: 2025-04-16
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2025-02-07
• Last updated: 2026-03-05

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated device study